
1. Technology overview
Positrigo AG is a Swiss medtech company based at Technoparkstrasse 1 in Zurich. It develops NeuroLF, an ultra-compact dedicated brain PET system aimed at making brain imaging for dementia and Alzheimer's diagnosis more accessible to hospitals and clinics.
NeuroLF is a dedicated brain PET scanner that needs little space, is simple to operate and is designed for patient comfort. Applications listed include dementia, neuro-oncology, epilepsy, movement disorders and research. The system holds FDA clearance (July 2024) and CE marking (October 2024), is sold in the US and EU through direct sales and distributors, and is installed at sites such as LMU Klinikum in Munich and outpatient neurology clinics in the United States.
2. Highlighted features & specifications
- Dedicated brain PET: ultra-compact scanner built only for brain imaging.
- Dementia focus: designed for Alzheimer's and dementia diagnosis.
- Broad applications: neuro-oncology, epilepsy, movement disorders and research.
- Regulatory status: FDA clearance in July 2024 and CE mark in October 2024.
- Quantitative harmonization: EARL accreditation achieved at LMU Klinikum Munich in 2026.
- Distribution: distributors in Spain and France plus direct sales in the US and Germany.
3. Potential application
Neurology and nuclear medicine departments in Vietnamese central hospitals could use NeuroLF for dementia work-up. Research institutes could use it in Alzheimer's clinical studies. Private imaging centres could add brain-only PET with a smaller footprint.
4. Benefits
Small space requirements make brain PET feasible for sites without a full PET suite. Simple operation and patient comfort are highlighted. Specialists quoted on the site say it can lower the cost of brain scans. EARL accreditation supports quantitative comparability across sites.
5. Market trends & opportunities
Demand for Alzheimer's diagnostics is rising as amyloid-targeting therapies expand, which increases the need for accessible brain PET. Vietnam's ageing population and growing neurology capacity at major hospitals could create interest, although no local presence is known.
6. Other information
Positrigo AG, Technoparkstrasse 1, 8005 Zurich, Switzerland. ISO 13485:2016 (2021 news), FDA clearance July 2024, CE mark October 2024. Financing round closed June 2025. Top 3 at the Swiss Medtech Award 2026. Distributors appointed in France and Spain in 2025; first Italian sale to the University Hospital of Genoa in December 2025.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































